6BX.F - Relevium Technologies Inc.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.0310
0.0000 (0.00%)
As of 8:15AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0310
Open0.0310
Bid0.0370 x 1700000
Ask0.0500 x 1400000
Day's Range0.0310 - 0.0310
52 Week Range0.0310 - 0.1100
Volume50,000
Avg. Volume769
Market Cap5.432M
Beta (3Y Monthly)0.97
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Relevium Announces Results of Annual Meeting of Shareholders and Updates Other Regulatory Matters

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the results of the Company's annual general and special meeting (the "AGM") held on September 6, 2019, in Montreal, Quebec.

  • GlobeNewswire

    Relevium Announces Record Sales From the Bioganix® Brand and Provides CBD Update

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that the company hit a record high in monthly sales in the month of July 2019 for its Bioganix® branded OTC business. “This record high in monthly sales was driven primarily by higher customer subscriptions, awareness optimization in the UK and the successful and recent launch of PushPullSystemTM, CardiaPro® and VisionPro®, a new series of high-end wellness products.” stated Abis Hussain, Chief Marketing Officer at Relevium. The Company launched two exclusive, evidence-based formulations of Provinal® Omega 7 targeting heart health and vision care earlier last month and the products continue to gain initial acceptance by existing and new customers of the Bioganix® brand.

  • GlobeNewswire

    Relevium Signs Exclusivity Agreement With SOSCannabis.com for Reimbursement for Pediatric Patients

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today it has executed an exclusivity agreement to partner with SOS cannabis Inc. (“SOSCannabis”), which will provide pediatric customers with the ability to obtain free legal representation to seek reimbursement for the costs of medical cannabinoid therapy from different government agencies for the treatment of medical conditions for pediatric patients. The partnership agreement will provide Relevium’s pediatric customers with access to an experienced legal and case management team, who will prepare the case file and seek retroactive and prospective reimbursement for parents of pediatric patients at no cost.

  • GlobeNewswire

    Relevium’s CEO Issues Letter of Clarification to Shareholders  

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today a letter from Aurelio Useche, CEO to shareholders to clarify misconceptions and rumours in the market about a compliance news release disseminated on July 1, 2019 by the Company pursuant to a request from the OTC Markets Group. The Management of Relevium or any publicly traded company has the responsibility to dispel unfounded rumours, misinformation or false statements which result in unusual market activity. As CEO, director and shareholder of Relevium Technologies Inc. I feel it necessary to issue this letter and issue a clear and direct clarification regarding inaccurate and misleading statements being made by independent blog and referral traffic investor website equity.guru and Mr. Chris Parry.

  • GlobeNewswire

    Relevium Issues Statement Regarding Recent Promotional Activity

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today that it has been made aware of and requested by the OTC Markets Group, Inc. to comment on recent promotional activity concerning its common shares traded on the OTCQB market. On June 27th, 2019, the OTC Markets Group sent the Company copies of three newsletters sent on June 25 and June 26, 2019 by SmallCapFirm, a third-party marketing and awareness firm utilized by StockWireNews, LLC (“StockWireNews”), which in turn was utilized by one of the Company’s marketing firms, Shore Thing Media, LLC (“Shore Thing”).

  • GlobeNewswire

    Relevium’s Biocannabix Positions Itself as an Important Player in Colombia as it Pursues Endo-Medical Cannabis Strategy for Latin America

    Relevium Technologies Inc. a Health and Wellness portfolio company listed on TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX” (the “Company” or “Relevium”) announced today it is positioning itself as an important player in the Colombian medical cannabis market  by cementing medical and research relationships in the country in order to establish clinical validation programs for its Endo Nutraceutical Supplements (ENS) and Oral Nutritional Supplements. On June 13th, 2019, the Company announced a binding LOI to acquire LifeLine Pharma SAS, a binding agreement to acquire the shares of Lifeline Pharma SAS, a Cali based cultivation and extraction business in the burgeoning agro-pharma market in Colombia.

  • GlobeNewswire

    Relevium to Hold Investor Call to Discuss LATAM Strategy June 28, 2019 at 1:00pm EST

    Relevium Technologies Inc. a Health and Wellness portfolio company listed on TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX” (the “Company” or “Relevium”), is pleased to announce it will be holding a shareholder and investor conference call to discuss its Latin American (LATAM) strategy and the upside potential of its recently announced acquisition in Colombia. It is estimated that Colombia is positioned to supply about 44% of the World’s market for medical cannabis and the acquisition of Lifeline Pharma SAS  (“LifeLine”) in Colombia is set to allow Biocannabix Health Corporation to target two important sources of revenues: (1) EU GMP pharma-grade extracts for export and (2) endo-nutraceutical (ENS) and oral nutritional supplements (ONS) for in-country distribution.

  • GlobeNewswire

    Relevium Takes Major Step in Latam to Acquire Lifeline Pharma in Cali, Colombia

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that Biocannabix Health Corporation (“Biocannabix”), a wholly-owned subsidiary of Relevium has executed on June 12, 2019 a binding agreement to acquire the shares of Lifeline Pharma SAS, a Cali based cultivation and extraction business in the burgeoning agro pharma market in Colombia. Multi-stage project with (1) an initial 5 hectares that includes the local offices, a laboratory, a fully enclosed greenhouse for tissue culture and micropropagation and an initial cultivation of over 200,000 square feet in open air green houses, (2) an option to expand to an additional 20 hectares or 2.2 million square feet of open air greenhouse cultivation and (3) the possibility to expand to another additional 60 hectares or 6.5 million square feet of cultivation.

  • GlobeNewswire

    Relevium Closes Private Placement Financing

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that it has closed a non-brokered private placement financing for a total of 15,350,000 units (the "Units") at $0.08 per Unit, for total gross proceeds of $1,228,000. Each Unit consists of one common share of Relevium and one common share purchase warrant entitling the holder to purchase one additional common share at $0.12 per share for a period of one year from the date of the issue. Relevium has the right to accelerate the expiry date of the Warrants if, at any time, the average closing price of Relevium’s common shares is equal to or greater than $0.15 for 10 consecutive trading days.

  • GlobeNewswire

    Relevium’s Biocannabix Executes LOI to Acquire 30% Interest in Weedsense, a Late Stage Applicant for Standard Processing and Medical Sales License

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce its wholly owned subsidiary Biocannabix Health Corporation (“Biocannabix”) has executed an LOI to acquire 30% of Weedsense Inc., a late stage applicant for standard processing and medical sales license. Weedsense Inc. (“Weedsense”) is building a wholesale and distribution business in Montreal, Québec.

  • GlobeNewswire

    Relevium Provides Corporate Update on Its Medical Cannabis Strategy

    Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide a corporate update on the Company’s positioning and strategy regarding medical cannabis and CBD Nutraceuticals. The Food and Drug Administration (the “FDA”), held a key public hearing last Friday regarding its role in regulating cannabis-derived products such as CBD as nutritional supplements. The FDA’s position is that although hemp is no longer an illegal substance under federal law, the FDA continues to regulate cannabis products under the Food, Drug, and Cosmetic Act (“FD&C Act”) and Section 351 of the Public Health Service Act.

  • GlobeNewswire

    Relevium Launches New Line of High-End Omega Fish Oils Targeting Inflammation, Heart and Vision    

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that its OTC business has launched a new line of omega fish oils based formulations targeting inflammation, heart and vision care. The Company has launched an initial two omega formulated products to support heart health and vision care: CardiaProtm and VisionProtm, leading the way to a complete line of scientifically formulated products targeting inflammation. Inflammation, which is a process by which the body's natural immune response seeks to protect us from infection with foreign organisms, such as bacteria and viruses.

  • GlobeNewswire

    Relevium Announces Private Share Purchase by CEO

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced today that Mr. Aurelio Useche, Chief Executive Officer, has agreed to purchase a total of 4,213,713 common shares of Relevium, representing approximately 3% of Relevium’s total shares outstanding, from Mr. Albertus Engelbrecht in a private transaction. Relevium is a publicly-traded company that operates in the health and wellness industry, including legal cannabis, with a primary focus on online distribution. The principal business of the Company is the identification, evaluation, acquisition and operations of brands and businesses in the Health and Wellness markets and medical cannabis.

  • GlobeNewswire

    Relevium Announces Reprice of the 2016 and 2017 Series Warrants

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced the re-pricing 12,398,500 warrants series 2017 with an original exercise price of $0.15 and expiring June 16, 2019 and 3,258,000 warrants of series 2016 with an original exercise price of $0.15 and expiring August 16, 2019. The series 2016 and 2017 have been repriced to $0.10 and the new exercise price is only valid for a period of 29 days starting today and expiring June 15, 2019. The warrant re-price is subject to final approval by the TSX Venture Exchange.

  • GlobeNewswire

    Relevium Reports Second Quarter Revenue Bounce Back for Fiscal 2019  

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to report second quarter results for fiscal 2019. During the second quarter ended December 2018, the Company’s revenue bounced back to $1,006,501 as compared to $968,474 in the second quarter of fiscal 2018. The Company also reported quarter-over-quarter increase in revenues from $985,051 reported for the first quarter of fiscal 2019.

  • GlobeNewswire

    Relevium Announces DTC Eligibility for the US Market

    Relevium Technologies Inc. (TSX.V: “RLV”,  OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce it has secured eligibility by The Depository Trust Company (DTC) for its shares on the OTC. DTC is a subsidiary of the Depository Trust & Clearing Corp. that manages the electronic clearing and settlement of publicly traded companies in the United States. DTC eligibility will simplify the process of trading and is expected to enhance liquidity and overall visibility in the US OTC capital markets, where the Company trades under the symbol "RLLVF".

  • GlobeNewswire

    Relevium Launches the Push and Pull System™, Targeting a New Revenue Stream in the Burgeoning Cosmeceutical Market

    Relevium Technologies Inc. (TSX.V: “RLV”,  OTC: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the new launch of the Push and Pull System™, an innovation in delivering a comprehensive solution for skin care, designed specifically for today’s active women. The Push & Pull System™ by Bioganix® is the first ever comprehensive natural anti-aging system for complete skin care that combines Collagen Protein supplements (PUSH) and naturally sourced Aloe Vera skin anti-aging cream (PULL). This new launch is targeting a brand-new revenue stream in the burgeoning cosmeceutical market, which is the fastest growing segment of the health and wellness Market.

  • GlobeNewswire

    Relevium Announces Investor Web Conference

    Relevium Technologies is pleased to host a town hall information web conference to discuss the company’s developments and answer shareholder inquiries. During the webcast, management will be discussing business development initiatives, product launches and expansion of the Bioganix® brand, the acquisition of Sleipnir and update on the progress of initiatives launched late last year. The Company will also discuss the roll out of the LeefyLyfe™ brand and the newly acquired license for Cannakids® by its Biocannabix business unit.

  • GlobeNewswire

    Relevium to Acquire Multi-Brand Company in the UK

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce it has executed a binding agreement to acquire 100% of the shares of Sleipnir Nutrition Ltd. (“Sleipnir”), a UK health and wellness multi-brand portfolio entrepreneurial company with products in superfood teas, skin care and beauty. The transaction is expected to close before the end of this month. “We are excited to continue to strengthen our branding and global reach capabilities with the strategic acquisition of Sleipnir,” stated Abis Hussain, Chief Marketing Officer of Relevium.

  • GlobeNewswire

    Relevium To Host Screenings of Documentary “Weed The People” Across Canada Today -- CFN Media

    In partnership with Executive Producer Ricki Lake, Director Abby Epstein, and CannaKids.org, Relevium will host a nation-wide screening of this compelling, emotional, and educational film that explores the potential benefits of medical cannabis oils for pediatric applications, followed by live discussions. The film follows the journey of five families with children battling cancer, and the introduction of cannabis oil into their treatment after the failure of conventional methods. “The film is an amazing journey into the potential opportunities of complementing traditional treatments for cancer and other illness in pediatric patients,” said Aurelio Useche, CEO of Relevium Technologies.

  • GlobeNewswire

    Relevium Announces the National Screening of “Weed the People” Movie Across Eight Major Cities

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce the national screening of “Weed the People” across eight Canadian cities on January 15, 2019. Relevium Technologies, in partnership with Executive Producer Ricki Lake, Director Abby Epstein and Cannakids.org, will be conducting a nation-wide screening of Weed the People, a compelling, emotional and educational film that explores the potential benefits of medical cannabis oils for pediatric applications. The film follows the journey of five families dealing with children suffering from cancer and the introduction of cannabis oil to treat their children following the failure of conventional treatments.

  • GlobeNewswire

    Relevium Provides Corporate Update

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to provide shareholders with a corporate update on the previously announced transaction with CannaKids and CK properties, as well as to announce an additional  convertible note financing with our partners under the June 2017 note purchase agreement. In order to comply with TSX Venture Exchange policies regarding investments into US based Cannabis assets, Relevium Technologies would like to announce that it has renegotiated and restructured the transaction as announced on October 16, 2018. In the original transaction, the Company announced that it would acquire an initial twenty five percent (25%) of the outstanding shares in CK Properties and its brand CannaKids and will concurrently obtain the Canadian exclusive rights for a total consideration of USD$2.7 million.

  • GlobeNewswire

    Relevium Launches Its Leefylyfe™ Organically Sourced Whole Plant Hemp Derived CBD Products in the UK

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to announce that it has launched its  Leefylyfe™ brand of organically sourced full spectrum hemp CBD products on a pre-order basis in the UK. The Company is launching three initial organically sourced, whole plant Hemp CBD rich oils in product and tincture formats that maintain a full spectrum of secondary cannabinoids, terpene profiles and flavonoids for wellbeing. The company plans to launch several exclusive formulations of its Leefylyfe™ branded products in 2019 and plans to extend sales to the rest of Europe.

  • GlobeNewswire

    Relevium Launches 30 New Bioganix® Gold Brand Products in Walmart.com

    On October 11, 2018, the Company announced it was targeting to launch 30 new products under its Bioganix® Gold Brand, which sell exclusively in Walmart.com. The Company has launched 14 out of the 30 new products and the balance is currently under the normal compliance review process and are expected to be live on Walmart.com and available to Walmart Shoppers over the next two weeks. “We are very excited about the addition of 30 new products to our Bioganix® Gold Line of nutraceuticals and skin care products sold exclusively through Walmart.com.

  • GlobeNewswire

    Relevium Adds Amazon Experts to the Team

    Relevium Technologies Inc. (TSX.V:“RLV”, OTCQB:“RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”) is pleased to announce it has retained Rohan Mendonza and his company, NForce Labs Inc., to lead its Amazon business. Rohan Mendonza, formerly Director of Operations at Amazon.com Inc., is the CEO of NForce Labs, Inc., an e-commerce consulting firm helping brands streamline supply chains, grow organic marketing, and optimize paid advertising services with the goal of maximizing clients’ return on investment.